Evidence map›Paper›PMID 41189708›Full record

ArticleFrontiers in cellular and infection microbiology2025

COVID-19 pandemic increased ESKAPEEc bloodstream infections and amplified carbapenem resistance in Chinese children: a multicenter surveillance study (2016-2023).

Xiaoqiang Li, Hongmei Xu, Cai Wang, Ruiqiu Zhao, Jiaying Wu, Hui Yu, Chuanqing Wang, Pan Fu, Jikui Deng, Chunzhen Hua and 12 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Xiaoqiang Li *Department of Clinical Laboratory, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorders. Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China.
Hongmei Xu *Infectious Disease Department, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorders. Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China.
Cai Wang *Department of Clinical Laboratory, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorders. Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China.
Ruiqiu Zhao *Infectious Disease Department, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorders. Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China.
Jiaying WuInfectious Disease Department, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorders. Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China.
Hui YuInfectious Disease Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Chuanqing WangDepartment of Clinical Microbiology Laboratory, Nosocomial Infection Control Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Pan FuDepartment of Clinical Microbiology Laboratory, Nosocomial Infection Control Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Jikui DengInfectious Disease Department, Shenzhen Children's Hospital, Shenzhen, China.
Chunzhen HuaInfectious Disease Department, Children's Hospital of Zhejiang University, Hangzhou, China.
Yinghu ChenInfectious Disease Department, Children's Hospital of Zhejiang University, Hangzhou, China.
Mingming ZhouDepartment of Medical Laboratory, Children's Hospital of Zhejiang University, Hangzhou, China.
Ting ZhangDigestive and Infectious Disease Department, Children's Hospital of Shanghai Jiaotong University, Shanghai, China.
Hong ZhangDepartment of Medical Laboratory, Children's Hospital of Shanghai Jiaotong University, Shanghai, China.
Yiping ChenPediatric Infectious Disease Department, Second Affiliated Hospital, and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Shifu WangDepartment of Medical Laboratory, Qilu Children's Hospital, Shandong University, Jinan, China.
Qing CaoInfectious Disease Department, Shanghai Children's Medical Center, Shanghai, China.
Huiling DengInfectious Disease Department, Xi'an Children's Hospital, Xi'an, China.
Huijun CaiDepartment of Medical Laboratory, Xi'an Children's Hospital, Xi'an, China.
Jianhua HaoInfectious Disease Department, Children's Hospital of Kaifeng City, Kaifeng, China.
Yuyang ZhouDepartment of Medical Laboratory, Children's Hospital of Kaifeng City, Kaifeng, China.
Chunmei JingDepartment of Clinical Laboratory, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorders. Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study investigated the long-term trends in the distribution and antibiograms of ESKAPEEc pathogens in neonatal and pediatric bloodstream infections (BSIs), shifts in minimum inhibitory concentration (MIC) of vancomycin and linezolid in Methods: A multicenter retrospective surveillance study was carried out from 2016 to 2023 at 12 tertiary pediatric hospitals across nine provinces and autonomous regions in China. The collected data were analyzed using GraphPad Prism 8 and WHONET 5.6. Temporal variations and linear trends were evaluated using chi-square or Fisher's exact tests. Results: A total of 10,051 ESKAPEEc strains accounted for 22.5% (10,051/44,675) of all BSIs, with 32.3% from neonatal BSIs and 67.7% from pediatric BSIs. The detection rate of ESKAPEEc pathogens increased for post the coronavirus disease 2019 (COVID-19) compared to the pre-COVID-19. Carbapenem resistance levels were 5.5% in Conclusions: The incidence of ESKAPEEc in BSIs has increased, and the rising resistance to imipenem and meropenem in

Indexed as

Anti-Bacterial AgentsBacteremiaCarbapenemsCOVID-19ChildChild, PreschoolChinaDrug Resistance, BacterialEast Asian PeopleFemaleHumansInfantInfant, NewbornLinezolidMaleMicrobial Sensitivity TestsAnti-Bacterial AgentsCarbapenemsLinezolidVancomycinantimicrobial resistancebloodstream infectionsdriftESKAPEEcneonatalpediatrictime trend

Identifiers

PMID41189708
PMCPMC12580251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.